Literature DB >> 1400409

p13suc1 suppresses the catalytic function of p34cdc2 kinase for intermediate filament proteins, in vitro.

M Kusubata1, T Tokui, Y Matsuoka, E Okumura, K Tachibana, S Hisanaga, T Kishimoto, H Yasuda, M Kamijo, Y Ohba.   

Abstract

The regulation of p34cdc2 kinase activity controls the entry into and exit from mitosis. Although genetic and biochemical evidence suggested close interactions between cyclins, p13suc1 and p34cdc2 kinase, the roles of p13suc1 on p34cdc2 kinase functions remain unclear. To examine the effects of p13suc1 on p34cdc2 kinase function we developed a simple purification procedure for p34cdc2 kinase, unassociated with p13suc1. The key to the purification procedures we used was buffer containing 0.5 M NaCl and 50% ethylene glycol, as a specific elutant of p34cdc2 kinase from p13suc1-Sepharose. This purified p34cdc2 kinase stoichiometrically phosphorylated vimentin and desmin. Exogenous p13suc1 suppressed the phosphorylation of these filament proteins by the kinase and prevented disassembly, although histone H1 phosphorylation was not affected. Peptide mapping analysis showed a similar extent of inhibition by p13suc1 for all five phosphorylation sites by p34cdc2 kinase of vimentin and desmin, hence these p13suc1-induced inhibitions are probably not site-specific. It thus appears that p13suc1 has a selective effect on the catalytic activity of p34cdc2 kinase for these filament proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400409

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Xe-p9, a Xenopus Suc1/Cks protein, is essential for the Cdc2-dependent phosphorylation of the anaphase- promoting complex at mitosis.

Authors:  D Patra; W G Dunphy
Journal:  Genes Dev       Date:  1998-08-15       Impact factor: 11.361

2.  A macrolide antibiotic, roxithromycin, inhibits the growth of human myeloid leukemia HL60 cells by producing multinucleate cells.

Authors:  M Nagai; H Yamada; S Nakada; K Ochi; T Nemoto; S Takahara; S Hoshina; J Horiguchi-Yamada
Journal:  Mol Cell Biochem       Date:  1995-03-23       Impact factor: 3.396

3.  Crystal structure of the cell cycle-regulatory protein suc1 reveals a beta-hinge conformational switch.

Authors:  Y Bourne; A S Arvai; S L Bernstein; M H Watson; S I Reed; J E Endicott; M E Noble; L N Johnson; J A Tainer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

4.  A p90(rsk) mutant constitutively interacting with MAP kinase uncouples MAP kinase from p34(cdc2)/cyclin B activation in Xenopus oocytes.

Authors:  A C Gavin; A Ni Ainle; E Chierici; M Jones; A R Nebreda
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

5.  Cloning and characterization of the Xenopus cyclin-dependent kinase inhibitor p27XIC1.

Authors:  J Y Su; R E Rempel; E Erikson; J L Maller
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 6.  Posttranslational modifications of desmin and their implication in biological processes and pathologies.

Authors:  Daniel L Winter; Denise Paulin; Mathias Mericskay; Zhenlin Li
Journal:  Histochem Cell Biol       Date:  2013-10-04       Impact factor: 4.304

7.  Mouse p87wee1 kinase is regulated by M-phase specific phosphorylation.

Authors:  R Honda; H Tanaka; Y Ohba; H Yasuda
Journal:  Chromosome Res       Date:  1995-08       Impact factor: 5.239

Review 8.  Regulation of Cdc28 cyclin-dependent protein kinase activity during the cell cycle of the yeast Saccharomyces cerevisiae.

Authors:  M D Mendenhall; A E Hodge
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

9.  Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase.

Authors:  T Izumi; J L Maller
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

10.  The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein.

Authors:  J A Endicott; M E Noble; E F Garman; N Brown; B Rasmussen; P Nurse; L N Johnson
Journal:  EMBO J       Date:  1995-03-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.